Sorrento Therapeutics Inc SRNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.25
- Bid/Ask
- — / —
- Market Cap
- $1.98 Mil
- Volume/Avg
- 36,678 / 132,210
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 949
Comparables
Valuation
|
Metric
|
SRNE
|
MCRB
|
IBRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | — | — |
Price/Sales | — | 315.43 | 1,657.81 |
Price/Cash Flow | — | — | — |
Price/Earnings
SRNE
MCRB
IBRX
Financial Strength
|
Metric
|
SRNE
|
MCRB
|
IBRX
|
|---|---|---|---|
Quick Ratio | 0.43 | 0.83 | 3.54 |
Current Ratio | 0.50 | 1.38 | 3.91 |
Interest Coverage | −80.16 | −9.50 | −3.17 |
Quick Ratio
SRNE
MCRB
IBRX
Profitability
|
Metric
|
SRNE
|
MCRB
|
IBRX
|
|---|---|---|---|
Return on Assets (Normalized) | −71.61% | −38.51% | −116.40% |
Return on Equity (Normalized) | — | — | — |
Return on Invested Capital (Normalized) | −231.73% | −73.47% | −242.84% |
Return on Assets
SRNE
MCRB
IBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jyvppvnhm | Mhc | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pvzwnxb | Drlbzm | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jfjvxcg | Wrqndz | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ndflpkgxs | Jwvrcp | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Dglzprlyq | Sqxth | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qpskssjy | Jjg | $29.2 Bil | |||
| Moderna Inc
MRNA
| Tcwrcdn | Bzy | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Qmvbdsrjg | Rkrx | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xytxjzbrr | Rdktq | $13.2 Bil | |||
| Incyte Corp
INCY
| Qmxdnrgr | Rchbb | $13.0 Bil |
United States